Biotech Values

[apljack]

NEO: NeoGenomics Revises Upward its Quarter 3 2013 Guidance

(This is very good news, demonstrating that the co. continues to execute on their plans to expand market share and provides the market with some assurance that they will continue to grow despite the prospect of medicare reimbursement cuts. Can they stay profitable in the face of cuts? Unknown at this point.)

http://finance.yahoo.com/news/neogenomics-revises-upward-quarter-3-110000994.html

FT. MYERS, Fla., Sept. 26, 2013 /PRNewswire/ -- NeoGenomics, Inc. (NEO) announced today that it was revising upward its previously issued guidance for Quarter 3, 2013. The Company now expects revenue of approximately $16.6 - $16.9 million and earnings per share of $0.01 - $0.02 in the third quarter. The Company had originally guided to revenue of $15.8 - $16.4 million and earnings per share of $0.00 - $0.01 on July 31, 2013.

Doug VanOort, the Company's Chairman and CEO, commented, "We experienced strong year-over-year revenue growth in July and August, and our rate of growth has continued to accelerate in September. This growth is broad-based, and is the result of a variety of growth initiatives we have made over the last eighteen months, including, but not limited to, increasing sales force productivity and various new product launches. We are scheduled to release our full third quarter financial results on October 23, 2013."

The Company reserves the right to adjust this guidance at any time based on the ongoing execution of its business plan. Current and prospective investors are encouraged to perform their own due diligence before buying or selling any of the Company's securities, and are reminded that the foregoing estimates should not be construed as a guarantee of future performance.


Best,,
aj